Key clinical point: In situ vaccination can produce responses in patients with indolent non-Hodgkin lymphoma, prompting regression of tumors that are directly targeted, as well as untreated tumors.
Major finding: At the target lesion, in situ vaccination produced two complete responses, six partial responses, and three cases of stable disease. At nontarget lesions, there was one complete response, two partial responses, six cases of stable disease, and two cases of progression.
Study details: Preclinical research and a phase 1/2 trial of 11 patients with indolent non-Hodgkin lymphoma.
Disclosures: The research was supported by Merck, Celldex Therapeutics, Oncovir, and Genentech. The authors reported relationships with the study sponsors and several other companies.
Hammerich L et al. Nat Med. 2019 Apr 8. doi: 10.1038/s41591-019-0410-x.